RESUMO
The prevalence of Barrett's esophagus is increasing in the United States and is a major risk factor for esophageal adenocarcinoma. This review serves to help primary care physicians and family practitioners better understand who should be screened for Barrett's esophagus, know the appropriate surveillance intervals for repeat endoscopy, and understand therapeutic options for the management of Barrett's esophagus.
Assuntos
Esôfago de Barrett/diagnóstico , Atenção Primária à Saúde/métodos , Vigilância de Evento Sentinela , Adenocarcinoma/diagnóstico , Adenocarcinoma/etiologia , Esôfago de Barrett/complicações , Esôfago de Barrett/terapia , Detecção Precoce de Câncer/métodos , Neoplasias Esofágicas/diagnóstico , Neoplasias Esofágicas/etiologia , HumanosRESUMO
Although the incidence of nonvariceal upper gastrointestinal bleeding (UGIB) has been decreasing worldwide, nonvariceal UGIB continues to be a significant problem. Even with the advent of advanced endoscopic procedures and potent medications to suppress acid production, UGIB carries significant morbidity and mortality. Some of the most common risk factors for nonvariceal UGIB include Helicobacter pylori infection, nonsteroidal antiinflammatory drugs (NSAIDs), aspirin, selective serotonin reuptake inhibitors, and other antiplatelet and anticoagulant medications. In patients with cardiovascular disease and kidney disease, UGIB tends to be more severe and has greater morbidity. Many of the newer NSAIDs have been removed from the market.